1. Home
  2. CGEN vs BW Comparison

CGEN vs BW Comparison

Compare CGEN & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • BW
  • Stock Information
  • Founded
  • CGEN 1993
  • BW 1867
  • Country
  • CGEN Israel
  • BW United States
  • Employees
  • CGEN N/A
  • BW N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • BW Building Products
  • Sector
  • CGEN Health Care
  • BW Industrials
  • Exchange
  • CGEN Nasdaq
  • BW Nasdaq
  • Market Cap
  • CGEN 125.3M
  • BW 119.1M
  • IPO Year
  • CGEN 2000
  • BW N/A
  • Fundamental
  • Price
  • CGEN $1.58
  • BW $5.57
  • Analyst Decision
  • CGEN
  • BW Strong Buy
  • Analyst Count
  • CGEN 0
  • BW 1
  • Target Price
  • CGEN N/A
  • BW $5.00
  • AVG Volume (30 Days)
  • CGEN 522.7K
  • BW 4.3M
  • Earning Date
  • CGEN 11-10-2025
  • BW 11-04-2025
  • Dividend Yield
  • CGEN N/A
  • BW N/A
  • EPS Growth
  • CGEN N/A
  • BW N/A
  • EPS
  • CGEN N/A
  • BW N/A
  • Revenue
  • CGEN $22,144,000.00
  • BW $724,905,000.00
  • Revenue This Year
  • CGEN N/A
  • BW N/A
  • Revenue Next Year
  • CGEN $208.08
  • BW $8.02
  • P/E Ratio
  • CGEN N/A
  • BW N/A
  • Revenue Growth
  • CGEN N/A
  • BW 48.90
  • 52 Week Low
  • CGEN $1.13
  • BW $0.22
  • 52 Week High
  • CGEN $2.66
  • BW $5.65
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 44.43
  • BW 76.14
  • Support Level
  • CGEN $1.61
  • BW $3.12
  • Resistance Level
  • CGEN $1.80
  • BW $5.57
  • Average True Range (ATR)
  • CGEN 0.11
  • BW 0.41
  • MACD
  • CGEN -0.03
  • BW 0.18
  • Stochastic Oscillator
  • CGEN 19.35
  • BW 95.62

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: